Cargando…

P1160: METHOTREXATE IN COMBINATION WITH IBRUTINIB, THIOTEPA, RITUXIMAB (R-MTO) FOLLOWED BY AUTOLOGOUS STEM-CELL TRANSPLANT FOR PRIMARY CNS LYMPHOMA

Detalles Bibliográficos
Autores principales:	Xing, LI-Jie, Wei, Hai-Chen, Liu, Dan, Wang, Hui, LI, Ping, Xie, Lin-Na, LI, Zeng-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431168/ http://dx.doi.org/10.1097/01.HS9.0000971536.90361.c0

Ejemplares similares

Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience
por: Suleman, Adam, et al.
Publicado: (2022)

High-dose methotrexate, thiotepa, orelabrutinib combined with or without rituximab in primary or secondary central nervous system diffuse large B-cell lymphoma: a single-center retrospective analysis
por: Li, Yufeng, et al.
Publicado: (2023)

International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma
por: Khwaja, Jahanzaib, et al.
Publicado: (2022)

Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma
por: Kondo, Eisei, et al.
Publicado: (2019)

Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma
por: Delphine, Lebon, et al.
Publicado: (2023)

A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial
por: Fox, Christopher P., et al.
Publicado: (2021)

Prolonged third complete remission after busulfan, thiotepa, and autologous stem cell transplant in a primary central nervous system lymphoma patient
por: Camus, Vincent, et al.
Publicado: (2018)

Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS
por: Nagle, Sarah J, et al.
Publicado: (2017)

1160. Ecological Study for Pulmonary Blastomycosis
por: Wang, James L, et al.
Publicado: (2020)

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma
por: Fowler, Nathan H., et al.
Publicado: (2020)

An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma
por: Nishikori, Momoko, et al.
Publicado: (2021)

The Roles of circMTO1 in Cancer
por: Liu, Wei, et al.
Publicado: (2021)

MBCL-03. RESULTS OF HIGH-DOSE THIOTEPA, CARBOPLATIN AND ETOPOSIDE WITH AUTOLOGOUS HEMATOPOIETIC STEM-CELL TRANSPLANTATION FOR PATIENTS WITH RECURRENT MEDULLOBLASTOMA
por: Gevorgian, Asmik, et al.
Publicado: (2020)

Microtubule nucleation promoters Mto1 and Mto2 regulate cytokinesis in fission yeast
por: Dundon, Samantha E. R., et al.
Publicado: (2020)

Whither thiotepa (for patients in the USA)?
por: Dardis, Christopher, et al.
Publicado: (2015)

Ibrutinib for rituximab-refractory Waldenström macro-globulinemia
por: Gavriatopoulou, Maria, et al.
Publicado: (2017)

PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE
por: Di Folca, S., et al.
Publicado: (2022)

Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib‐based combination therapy: A real‐world experience of off‐label ibrutinib use
por: Chen, Feili, et al.
Publicado: (2020)

CD 5+ Peripheral B Cell Lymphoma With Transformation to CD 5+ Diffuse Large B Cell Lymphoma in the CNS: A Case Report Treated With Rituximab, High Dose Methotrexate, Cytarabine, and Intrathecal Methotrexate
por: Uczkowski, Dariusz, et al.
Publicado: (2022)

Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort
por: Yerram, Prakirthi, et al.
Publicado: (2023)

R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience
por: Lee, Ji Yun, et al.
Publicado: (2021)

Thiotepa in the treatment of advanced breast cancer.
por: Lyons, A. R., et al.
Publicado: (1965)

Benign Cutaneous Cysts: A Comprehensive Analysis of 1160 cases
por: Chughtai, Anila, et al.
Publicado: (2023)

Bortezomib/ibrutinib/rituximab: Various toxicities: case report
Publicado: (2021)

High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors
por: Hara, Junichi, et al.
Publicado: (2022)

Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
por: Modelevsky, Lisa, et al.
Publicado: (2018)

SS-4 High dose chemotherapy with autologous hematopoietic stem cell transplantation for CNS lymphoma
por: Kondo, Eisei
Publicado: (2020)

Phenotypic variability of MTO1-deficiency
por: Finsterer, Josef, et al.
Publicado: (2018)

Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen
por: Young, Patricia A., et al.
Publicado: (2020)

Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse
por: Oh, Timothy S., et al.
Publicado: (2022)

A Successful Treatment of Relapsed Primary CNS Lymphoma Patient with Intraventricular Rituximab Followed by High-Dose Chemotherapy with Autologous Stem Cell Rescue
por: Hong, Sung Jin, et al.
Publicado: (2009)

Correction: High-dose thiotepa, in conjunction with melphalan, followed by autologous hematopoietic stem cell transplantation in patients with pediatric solid tumors, including brain tumors
por: Hara, Junichi, et al.
Publicado: (2022)

The Combined Thiotepa and Testosterone Treatment of Cancer of the Breast
por: Brown, I. Scott, et al.
Publicado: (1964)

Ibrutinib and rituximab induced rapid response in refractory Richter syndrome
por: Lamar, Zanetta, et al.
Publicado: (2015)

Sustained Complete Remission in Multi-Relapsed Primary CNS Lymphoma Treated with Ibrutinib Monotherapy: A Case Report
por: Mair, Anna, et al.
Publicado: (2021)

Successful Consolidation/Maintenance Therapy with Single Agent Ibrutinib for Primary CNS Lymphoma after Initial Induction Therapy
por: Du, Steven, et al.
Publicado: (2022)

The genotypic and phenotypic spectrum of MTO1 deficiency
por: O'Byrne, James J., et al.
Publicado: (2018)

P1089: ZANUBRUTINIB-RITUXIMAB CHEMO-FREE THERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA
por: Qu, Chang-Ju, et al.
Publicado: (2023)

Treatment of Indian Kala-Azar with a New Antimony Compound: Nu-1160
por: Gupta, P. C. Sen, et al.
Publicado: (1952)

ML-8 HIGH-DOSE CHEMOTHERAPY SUPPORTED BY AN AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED PRIMARY CNS LYMPHOMA
por: Mishima, Kazuhiko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fbhqh4nl75oj41ifo1i232lcd0